Clinical trials recruiting for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
11
Recruiting trials
12
US states with sites
19
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| South Carolina | 2 |
| Utah | 2 |
| Alabama | 1 |
| California | 1 |
| Iowa | 1 |
| Kansas | 1 |
| Massachusetts | 1 |
| Minnesota | 1 |
| North Carolina | 1 |
| Ohio | 1 |
| Pennsylvania | 1 |
| Tennessee | 1 |
Top cities
Myrtle Beach, South Carolina 2Salt Lake City, Utah 2Birmingham, Alabama 1Boston, Massachusetts 1Charleston, South Carolina 1Cleveland, Ohio 1Durham, North Carolina 1Iowa City, Iowa 1Minneapolis, Minnesota 1Nashville, Tennessee 1
Self-screener
Recruiting trials
- A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
- A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
- Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
- How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany
- Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment
- Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
- PROCARE - PROstate Cancer Real World Evidence Registry
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
- Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
- Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Related conditions
Trials recruiting for Metastatic Hormone-sensitive Prostate Cancer (mHSPC) often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Non-metastatic Castration-resistant Prostate Cancer 4Metastatic Castration-resistant Prostate Cancer (mCRPC) 18Metastatic Castration-resistant Prostate Cancer 67Depression 1463Biochemical Recurrence of Malignant Neoplasm of Prostate 4
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.